AlphaCentric Advisors’s bluebird bio BLUE Stock Holding History

AlphaCentric Advisors’s Portfolio BLUE Stock Details BLUE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-2,470	Closed	-$612K	–	228
2021 Q3	$612K	Sell	2,470 -78	-3%	-$22.3K	0.16%	58
2021 Q2	$1.05M	Sell	2,548 -347	-12%	-$137K	0.29%	22
2021 Q1	$1.13M	Buy	2,895 +2,185	+308%	+$1.08M	0.38%	17
2020 Q4	$398K	Buy	+710	New	+$450K	0.17%	31
2020 Q3	–	Sell	-12	Closed	-$9K	–	167
2020 Q2	$9K	Buy	+12	New	+$9.05K	0.01%	136

Other funds holding BLUE

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

AlphaCentric Advisors's BLUE Position: Q4 2021 in Review

AlphaCentric Advisors sold out of bluebird bio (BLUE) in Q4 2021, closing a stake of 2,470 shares — an estimated $612K sold.

AlphaCentric Advisors first reported a position in BLUE in Q2 2020 and held it in 5 quarters. The position peaked at $1.13M in Q1 2021. 172 funds tracked by Wall St. Rank hold BLUE as of Q4 2021.

AlphaCentric Advisors reported no remaining bluebird bio position as of Q4 2021 after selling out during the quarter.
AlphaCentric Advisors sold 2,470 bluebird bio shares in Q4 2021, an estimated $612K.
AlphaCentric Advisors first reported a position in bluebird bio in Q2 2020 and held it in 5 quarters.
AlphaCentric Advisors's bluebird bio position peaked at $1.13M in Q1 2021.
172 funds tracked by Wall St. Rank held bluebird bio as of Q4 2021.

Based on AlphaCentric Advisors's 13F filing for Q4 2021, filed 25 Feb 2022.